NKGen Biotech Inc. has received FDA expanded access for its investigational new drug application, allowing the use of its cell therapy for the treatment of various neurodegenerative diseases.
The Santa Ana-based clinical stage biopharmaceutical company is currently testing the therapy, called troculeucel, in a Phase 2a trial that’s focused on moderate-stage Alzheimer’s disease.
With this authorization, the company can treat other diseases including Parkinson’s and multiple sclerosis.
NKGen fell 9.4% to 24 cents and a $18 million market cap following the announcement.
Shares in the company have fallen 97% since going public have fallen nearly 97% since going public via a reverse merger with a SPAC in 2023.
